Lilly, Novo Nordisk fight insulin biosimilars with tweaks to FDA draft guidance
As Americans with diabetes continue to die because they cannot afford their insulin, two of the three insulin manufacturers in the US are doing their …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
